BioLineRx Ltd.
BLRX
Price:
$0.2781
Market Cap:
$38.31M
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in...[Read more]
Industry
Biotechnology
IPO Date
2011-07-27
Stock Exchange
NASDAQ
Ticker
BLRX
PE Ratio
[-0.62]
ROE
[-225.62%]
Current Ratio
[1.61]
Dividend Yield
[0%]
Enterprise Value
[59.94M]
Dividend History
The ROE as of November 2024 (TTM) for BioLineRx Ltd. (BLRX) is -225.62%
According to BioLineRx Ltd.’s latest financial reports and current stock price. The company's current ROE is -225.62%. This represents a change of 294.33% compared to the average of -57.22% of the last 4 quarters.
BioLineRx Ltd. (BLRX) Historical ROE (quarterly & annually)
How has BLRX ROE performed in the past?
The mean historical ROE of BioLineRx Ltd. over the last ten years is -97.04%. The current -225.62% ROE has changed 132.51% with respect to the historical average. Over the past ten years (40 quarters), BLRX's ROE was at its highest in in the June 2024 quarter at 3.46%. The ROE was at its lowest in in the September 2023 quarter at -122.00%.
Average
-97.04%
Median
-45.64%
Minimum
-458.40%
Maximum
-30.25%
BioLineRx Ltd. (BLRX) ROE by Quarter and Year
Discovering the peaks and valleys of BioLineRx Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.02%
Maximum Annual ROE = -30.25%
Minimum Annual Increase = -78.79%
Minimum Annual ROE = -458.40%
| Year | ROE | Change |
|---|---|---|
| 2023 | -458.40% | 1.02% |
| 2022 | -40.80% | -1.29% |
| 2021 | -41.34% | -70.56% |
| 2020 | -140.41% | 74.84% |
| 2019 | -80.31% | 44.51% |
| 2018 | -55.57% | 20.67% |
| 2017 | -46.05% | 1.83% |
| 2016 | -45.23% | 49.53% |
| 2015 | -30.25% | -5.57% |
| 2014 | -32.03% | -78.79% |
BioLineRx Ltd. (BLRX) Average ROE
How has BLRX ROE performed in the past?
The current ROE of BioLineRx Ltd. (BLRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-180.18%
5-year avg
-152.25%
10-year avg
-97.04%
BioLineRx Ltd. (BLRX) ROE vs. Peers
How is BLRX’s ROE compared to its peers?
BioLineRx Ltd.’s ROE is greater than Ardelyx, Inc. (-46.60%), greater than Lexicon Pharmaceuticals, Inc. (-107.38%), less than Seres Therapeutics, Inc. (60.75%), less than ImmunityBio, Inc. (86.39%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than Mereo BioPharma Group plc (-69.11%), greater than Inozyme Pharma, Inc. (-88.42%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than Leap Therapeutics, Inc. (-116.24%), less than Verrica Pharmaceuticals Inc. (1.30%), greater than Verona Pharma plc (-79.64%), less than Galera Therapeutics, Inc. (21.95%), greater than Arcutis Biotherapeutics, Inc. (-119.11%), greater than Protalix BioTherapeutics, Inc. (-30.89%), greater than Cidara Therapeutics, Inc. (-219.21%), greater than Fortress Biotech, Inc. (-240.30%), less than Mustang Bio, Inc. (429.53%), greater than Achilles Therapeutics plc (-54.57%), less than Aptose Biosciences Inc. (1.03%), greater than Fortress Biotech, Inc. (-240.30%),
| Company | ROE | Market cap |
|---|---|---|
| -46.60% | $1.26B | |
| -107.38% | $312.11M | |
| 60.75% | $131.23M | |
| 86.39% | $3.55B | |
| -32.51% | $57.64M | |
| -69.11% | $575.61M | |
| -88.42% | $180.51M | |
| -32.76% | $491.80M | |
| -116.24% | $97.71M | |
| 1.30% | $45.35M | |
| -79.64% | $3.18B | |
| 21.95% | $2.07M | |
| -119.11% | $1.19B | |
| -30.89% | $124.44M | |
| -219.21% | $143.75M | |
| -240.30% | $44.44M | |
| 429.53% | $9.63M | |
| -54.57% | $43.57M | |
| 1.03% | $3.71M | |
| -240.30% | $42.11M |
Build a custom stock screener for BioLineRx Ltd. (BLRX) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioLineRx Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
BioLineRx Ltd. (BLRX) and other stocks custom spreadsheet templates
The easiest way to analyze a company like BioLineRx Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is BioLineRx Ltd.'s ROE?
How is the ROE calculated for BioLineRx Ltd. (BLRX)?
What is the highest ROE for BioLineRx Ltd. (BLRX)?
What is the 3-year average ROE for BioLineRx Ltd. (BLRX)?
What is the 5-year average ROE for BioLineRx Ltd. (BLRX)?
How does the current ROE for BioLineRx Ltd. (BLRX) compare to its historical average?